The Biosimilars Council, a division of US off-patent group the Association for Accessible Medicines, has applauded US president Joe Biden’s latest move to eliminate the biosimilar interchangeability designation in his fiscal year 2025 budget request.
Calling interchangeability an “arbitrary distinction”, the Biosimilars Council said that the US is the “only country in the world with this
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?